Purchase this article with an account.
T. J. McCulley, A. Chen, M. K. Yoon; Late Recurrence of Orbital and Systemic Reactive Lymphoid Hyperplasia Following Clinical Resolution With Rituximab Treatment. Invest. Ophthalmol. Vis. Sci. 2010;51(13):3529.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The role of rituximab, a monoclonal antibody to B-cell marker CD20, in the management of lymphoproliferate disease continues to expand. In this report, we describe two patients with widespread RLH involving the orbits bilaterally as well as extraorbital sites.
Interventional small case series.
Orbital RLH is a polyclonal lymphoid proliferation, without an identifiable monoclonal subpopulation or other marker of malignancy. Effectiveness of rituximab in the treatment of B-cell non-Hodgkin lymphoma is well documented. Given the predominance of CD20 positive B cells in RLH, it is not surprising that rituximab would be effective. Although initially complete clinical resolution was seen in both patients, late recurrences occurred. These cases illustrate the need for long term observation of such patients.
This PDF is available to Subscribers Only